OncoSec Medical Inc. (ONCS) Issues Quarterly Earnings Results, Misses Estimates By $0.04 EPS
OncoSec Medical Inc. (NASDAQ:ONCS) released its quarterly earnings results on Thursday. The company reported ($0.39) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.35) by $0.04.
Shares of OncoSec Medical (NASDAQ:ONCS) traded up 4.19% during midday trading on Thursday, reaching $1.74. 185,847 shares of the company’s stock were exchanged. The firm has a 50 day moving average price of $1.72 and a 200 day moving average price of $1.84. OncoSec Medical has a 12 month low of $1.36 and a 12 month high of $4.61. The company’s market cap is $30.69 million.
A hedge fund recently raised its stake in OncoSec Medical stock. Vanguard Group Inc. increased its stake in shares of OncoSec Medical Inc. (NASDAQ:ONCS) by 3.1% during the second quarter, according to its most recent filing with the SEC. The fund owned 430,031 shares of the company’s stock after buying an additional 13,025 shares during the period. Vanguard Group Inc. owned 2.44% of OncoSec Medical worth $705,000 as of its most recent filing with the SEC. 7.42% of the stock is currently owned by institutional investors and hedge funds.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/10/13/oncosec-medical-inc-oncs-issues-quarterly-earnings-results-misses-estimates-by-0-04-eps.html
Several equities analysts recently commented on ONCS shares. Maxim Group downgraded shares of OncoSec Medical to a “buy” rating and decreased their price target for the company from $17.00 to $5.00 in a research note on Thursday, July 21st. Rodman & Renshaw started coverage on shares of OncoSec Medical in a research note on Thursday, July 21st. They issued a “buy” rating and a $6.00 price target on the stock.
About OncoSec Medical
OncoSec Medical Incorporated is a biotechnology company focused on designing, developing and commercializing gene therapies, therapeutics and medical approaches to stimulate and guide an anti-tumor immune response for the treatment of cancer. The Company’s portfolio includes biologic immunology therapeutic product candidates intended to treat a range of tumor types.
Receive News & Ratings for OncoSec Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoSec Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.